Merck partners with Agenus for cancer immunotherapies
Executive Summary
Agenus Inc. (developing checkpoint modulators, heat-shock protein vaccines, and adjuvants for cancer and infectious diseases) agreed to use its 4-Antibody Retrocyte Display platform to discover fully human antibodies against two of Merck & Co. Inc.’s immune checkpoint targets for cancer. Merck gets rights to develop and sell the resulting compounds.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice